ADMA Biologics Inc (ADMA)

Return on assets (ROA)

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (ttm) US$ in thousands 197,673 68,132 34,788 -3,645 -28,240 -22,827 -40,292 -47,686 -65,905 -70,322 -73,135 -78,275 -71,647 -74,406 -73,610 -74,883 -75,748 -66,901 -61,422 -54,456
Total assets US$ in thousands 488,678 390,618 376,399 350,875 329,182 348,997 343,027 340,788 348,461 300,558 296,932 308,032 276,253 238,640 232,814 235,667 207,673 189,976 191,542 210,524
ROA 40.45% 17.44% 9.24% -1.04% -8.58% -6.54% -11.75% -13.99% -18.91% -23.40% -24.63% -25.41% -25.94% -31.18% -31.62% -31.77% -36.47% -35.22% -32.07% -25.87%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $197,673K ÷ $488,678K
= 40.45%

The return on assets (ROA) of ADMA Biologics Inc has exhibited a significant improvement over the analyzed period. Starting from negative percentages, the ROA steadily increased from -25.87% as of March 31, 2020, to peak at 40.45% as of December 31, 2024. This suggests that the company's ability to generate profits from its assets has strengthened considerably over time. The positive trend in ROA indicates that ADMA Biologics Inc has been able to efficiently utilize its assets to generate earnings and improve its overall financial performance.